Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 in High-Grade Extrapulmonary Neuroendocrine Carcinoma
NCT04042714Phase 2Terminated
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Aug 2019
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil in neuroendocrine carcinoma (NEC), sponsored by Baylor Scott & White Research Institute. Primary endpoint: Overall Response Rate at 24 months. Started Aug 2019; status: terminated.
02
Drugs
trifluridine + tipiracil
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT04042714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042714.